전체 프로그램

ADC 890 · Antibody 4071 · CGT 2714 · 다음 갱신 D-4 · 마지막 9월 2일

PopularRecently updatedCuratedMost trialsNeeds refreshORRLatestPhase 3FDA approved1,016 programs
AntibodyCurated CoreFDABristol Myers SquibbApproved

nivolumab (Opdivo, BMS-936558)

Melanoma, NSCLC, RCC, HCC, MSI-H tumors, and others · PD-1

#PD-1#Antibody#Approved#FDA-approved#BioJungboMoa-pick+5
Trials 1280Status Approved
AntibodyCurated CoreFDASanofiApproved

dupilumab (Dupixent, REGN668)

Atopic dermatitis, asthma, CRSwNP, EoE, prurigo nodularis · IL-4Rα

#IL-4R#Antibody#Approved#FDA-approved#BioJungboMoa-pick+5
Trials 278Status Approved
AntibodyCurated CoreFDAAmgenApproved

etanercept (Enbrel, TNFR-Fc)

RA, PsA, AS, plaque psoriasis, JIA · TNF (decoy receptor)

#TNFdecoyreceptor#Antibody#Approved#FDA-approved#BioJungboMoa-pick+5
Trials 236Status Approved
ADCCurated CoreFDAAstellasMMAE (monomethyl auristatin…Approved

enfortumab vedotin (Padcev, ASG-22ME, enfortumab-vedotin-ejfv)

Locally advanced or metastatic urothelial carcinoma · Nectin-4

#Nectin-4#ADC#Approved#FDA-approved#BioJungboMoa-pick+5
Trials 201Status Approved
AntibodyCurated CoreFDAJohnson & JohnsonApproved

ustekinumab (Stelara, Wezlana)

Psoriasis, psoriatic arthritis, Crohn's disease, ulcerative colitis · IL-12 / IL-23 (p40)

#IL-12IL-23p40#Antibody#Approved#FDA-approved#BioJungboMoa-pick+5
Trials 195Status Approved
ADCCurated CoreFDARocheMMAE (maytansinoid)Approved

ado-trastuzumab emtansine (Kadcyla, T-DM1, ado-trastuzumab emtansine / T-DM1)

HER2+ breast cancer · HER2

#HER2#ADC#Approved#FDA-approved#BioJungboMoa-pick+5
Trials 178Status Approved
AntibodyCurated CoreFDAJohnson & JohnsonApproved

teclistamab (Tecvayli, JNJ-64007957, teclistamab-cqyv)

Relapsed or refractory multiple myeloma · BCMA × CD3

#BCMACD3#Antibody#Approved#FDA-approved#BioJungboMoa-pick+5
Trials 132Status Approved
AntibodyCurated CoreFDAAbbVieApproved

risankizumab-rzaa (Skyrizi, BI 655066, risankizumab)

Plaque psoriasis, PsA, Crohn's disease, ulcerative colitis · IL-23 p19

#IL-23p19#Antibody#Approved#FDA-approved#BioJungboMoa-pick+5
Trials 110Status Approved
ADCCurated CoreFDAstaleRochevedotin, rituximab, cycloph…Phase 3

Polatuzumab Vedotin (Polatuzumab Vedotin)

Large B-Cell Lymphoma · FRα

#FR#ADC#Phase3#FDA-approved#BioJungboMoa-pick+5
Trials 91Status Recruiting
AntibodyCurated CoreFDARocheApproved

glofitamab (Columvi, RO7082859, glofitamab-gxbm)

Relapsed or refractory diffuse large B-cell lymphoma · CD20 × CD3

#CD20CD3#Antibody#Approved#FDA-approved#BioJungboMoa-pick+5
Trials 90Status Approved
AntibodyCurated CoreFDAJohnson & JohnsonApproved

guselkumab (Tremfya, CNTO 1959)

Plaque psoriasis, psoriatic arthritis, ulcerative colitis, Crohn's disease · IL-23 p19

#IL-23p19#Antibody#Approved#FDA-approved#BioJungboMoa-pick+5
Trials 87Status Approved
ADCCurated CoreFDAGSKMMAFApproved

belantamab mafodotin (Blenrep, GSK2857916)

Multiple myeloma · BCMA

#BCMA#ADC#Approved#FDA-approved#BioJungboMoa-pick+5
Trials 78Status Discontinued
AntibodyCurated CoreFDAUCBApproved

bimekizumab (Bimzelx, UCB4940, bimekizumab-bkzx)

Plaque psoriasis, psoriatic arthritis, axial spondyloarthritis, hidradenitis suppurativa · IL-17A / IL-17F

#IL-17AIL-17F#Antibody#Approved#FDA-approved#BioJungboMoa-pick+5
Trials 58Status Approved
AntibodyCurated CoreFDAGenmabApproved

epcoritamab (Epkinly, GEN3013, Tepkinly, epcoritamab-bysp)

Relapsed or refractory diffuse large B-cell lymphoma and follicular lymphoma · CD20 × CD3

#CD20CD3#Antibody#Approved#FDA-approved#BioJungboMoa-pick+5
Trials 57Status Approved
AntibodyCurated CoreFDARocheApproved

faricimab (Vabysmo, RG7716, faricimab-svoa)

Wet AMD, diabetic macular edema, macular edema following retinal vein occlusion · Ang-2 / VEGF-A

#Ang-2VEGF-A#Antibody#Approved#FDA-approved#BioJungboMoa-pick+5
Trials 53Status Approved
AntibodyCurated CoreFDAargenxApproved

efgartigimod (Vyvgart, ARGX-113, Vyvgart Hytrulo, efgartigimod alfa-fcab)

Generalized myasthenia gravis (AChR antibody positive), chronic inflammatory demyelinating polyneuropathy · FcRn (neonatal Fc receptor)

#FcRnneonatalFcreceptor#Antibody#Approved#FDA-approved#BioJungboMoa-pick+5
Trials 48Status Approved
CGTCurated CoreFDAIovance BiotherapeuticsApproved

lifileucel (Amtagvi, LN-144, tumor infiltrating lymphocyte)

Unresectable or metastatic melanoma after PD-1 blockade · Polyclonal tumor neoantigens (TIL)

#PolyclonaltumorneoantigensTIL#CGT#Approved#FDA-approved#BioJungboMoa-pick+5
Trials 47Status Approved
AntibodyCurated CoreFDAAmgenApproved

tarlatamab (Imdelltra, AMG 757, tarlatamab-dlle)

Extensive-stage small cell lung cancer after platinum-based chemotherapy · DLL3 × CD3

#DLL3CD3#Antibody#Approved#FDA-approved#BioJungboMoa-pick+4
Trials 39Status Approved
ADCCurated CoreFDAAbbVieDM4 (maytansinoid, tubulin …Approved

mirvetuximab soravtansine (Elahere, IMGN853, mirvetuximab-soravtansine-gynx)

FRα-positive platinum-resistant ovarian, fallopian tube, or primary peritoneal cancer · FRα (folate receptor alpha)

#FRfolatereceptoralpha#ADC#Approved#FDA-approved#BioJungboMoa-pick+5
Trials 32Status Approved
CGTCurated CoreFDAJohnson & JohnsonApproved

ciltacabtagene autoleucel (Carvykti, cilta-cel, LCAR-B38M, JNJ-68284528)

Relapsed or refractory multiple myeloma · BCMA

#BCMA#CGT#Approved#FDA-approved#BioJungboMoa-pick+5
Trials 29Status Approved

1 / 51 pages

← PreviousNext →